DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: Uber, Intel, Lyft, Shopify, Rivian and more
▼ + stars: | 2024-05-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +5 min

The company's overall revenue exceeded expectations, coming in at $10.13 billion versus analysts' estimate of $10.11 billion, per LSEG. Lyft – The ride-sharing company surged 5% after the company reported faster-than-expected growth in the first quarter. Lyft reported $1.28 billion in revenue, higher than the FactSet consensus of $1.16 billion. Arista Networks – Shares jumped 7% after the company reported better-than-expected first quarter results. Teva Pharmaceuticals — Shares advanced nearly 14% after the company reported better-than-expected revenue in the first quarter.

Persons: Lyft, FactSet, Rivian, Coupang, LSEG, Twilio, –, —, Samantha Subin, Tanaya Macheel, Michelle Fox, Alex Harring Organizations: Technologies, Revenue, LSEG, Intel, Department of Commerce, Huawei, Lyft, Electronic Arts, EA, Farfetch, Arista Networks –, Arista, Dutch Bros, Bros, Pharmaceuticals, Management Locations: China, Korea

☆ Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
▼ + stars: | 2024-05-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — putting embattled shares under pressure. BHC YTD mountain Bausch Health YTD Bottom line Along with quarterly results, Bausch Health reaffirmed forward guidance. While not necessarily expected to see a massive increase in adoption in the future like Lilly's GLP-1s, Xifaxan currently accounts for 41% of Bausch Health sales, excluding B+L. Breaking that down: $4.7 billion to $4.85 billion are attributable to Bausch Health (implying 2% to 5% organic growth), with $4.6 billion to $4.7 billion attributable to Bausch + Lomb. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Bausch, Eli Lilly, It's, Xifaxan, Jim Cramer's, Jim Cramer, Jim, Rafael Henrique Organizations: Health, Bausch Health, Norwich Pharmaceuticals, Amneal Pharmaceuticals, Food and Drug Administration, Management, CNBC Locations: generics, Norwich

☆ Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and Colgate
▼ + stars: | 2024-04-26 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. "I've been itching to buy Devon " again for the CNBC Investing Club portfolio . Snap : The social media company reported a much better-than-expected quarter with higher revenue and active users. Colgate-Palmolive : The consumer products giant had a strong quarter with organic sales up 9.8% and a full-year sales guidance raise. I admit that," Cramer said, referring to Procter & Gamble , which is a stock owned by the Investing Club.

Persons: Jim Cramer's, Jim Cramer, Cramer, Chevron, Botox, Colgate, — Organizations: CNBC, Club, Chevron, Intel, Colgate, Palmolive, Procter, Procter & Gamble, Investing Locations: Devon

☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
▼ + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +13 min

Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.

Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California

☆ The 4 most promising anti-aging drugs investors are sleeping on, according to a leading longevity researcher
▼ + stars: | 2024-03-08 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

Existing drugs could potentially be repurposed for longevity, a leading researcher says. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . But for now, he says, there are some cheap old drugs available that may help make people feel new again. AdvertisementResearching potential anti-aging drugs that are already approved to treat other conditions has some clear benefits over other interventions. Researchers suspect that the same blood sugar-regulating benefits of these drugs can also help stave off many age-related diseases.

Persons: —, Nir Barzilai, Barzilai, Metformin Francis Dean, Corbis Organizations: Service, Institute for Aging Research, Albert Einstein College of Medicine, US Food and Drug Administration, Getty Locations: Singapore, South

☆ Biden administration examining role of supply chain middlemen in generic drug shortages
▼ + stars: | 2024-02-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

They are group purchasing organizations, which broker drug purchases for hospitals and other health-care providers, and drug wholesalers, which buy medicines from manufacturers and distribute them to providers. But the Biden administration is zeroing in on other players in the drug supply chain to uncover the "root causes and potential solutions" to ongoing shortages. The Federal Trade Commission on Wednesday said it is examining the role that drug wholesalers and companies that purchase medicines for U.S. health-care providers play in shortages of generic drugs, which account for the majority of Americans' prescriptions. Group purchasing organizations and wholesalers have gotten limited attention on Capitol Hill, even as reining in high drug costs has become a key priority among lawmakers in both chambers. PBMs contend that manufacturers are responsible for high drug prices, while drugmakers say rebates and fees collected by those middlemen force them to increase list prices for products.

Persons: Biden, Doug Farrar, Cencora Organizations: FTC, Department of Health, Human Services, Federal Trade Commission, Public Affairs, CNBC, HHS, Cardinal Health, Group, Capitol, CNBC PRO Locations: U.S

☆ Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
▼ + stars: | 2024-02-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face competition from cheaper generics. Adjusting for one-time items, the company reported $2.95 per share. But the company expects its pharmaceutical revenue, which includes product revenue and its 50% share of Leqembi sales, to be flat this year compared to 2023.

Persons: Biogen, LSEG, Biogen's, Leqembi Organizations: LSEG, Biogen, Food and Drug, Reata Pharmaceuticals, FDA Locations: U.S

☆ Here are Monday's biggest analyst calls: Netflix, Nvidia, Apple, Meta, Lowe's, Walmart, Target, Pepsi & more
▼ + stars: | 2024-02-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

JPMorgan upgrades Lowe's to overweight from neutral JPMorgan said investors should buy the stock ahead of earnings later this month. JPMorgan reiterates Netflix as overweight JPMorgan said it's standing by its overweight rating on shares of Netflix. Loop reiterates Meta as buy Loop raised its price target on the stock to $550 per share from $440. Loop reiterates Alphabet as hold Loop raised its price target on the stock to $155 per share from $140. " UBS reiterates Target as buy UBS says Target shares are "compelling."

Persons: Evercore, it's, wouldn't, Rivian, Piper Sandler, Piper, Jefferies, Willis Towers Watson, URBN, Morgan Stanley downgrades Hershey, Morgan Stanley, Morgan Stanley downgrades XPO, Stifel, Raymond James downgrades, Raymond James, Melius, Roth, Guggenheimer, Guggenheim Organizations: Apple, Barclays, Walmart, EV, JPMorgan, generics, UFC, WWE, Netflix, Citi, Willis, PepsiCo, PEP, LT, UBS, Urban Outfitters, Google, 4Q, Bulls, Target, Bank of America, of America, Bank of America downgrades Duke Energy, Duke Energy, Brands, Nvidia, Deutsche Bank, Industries, Deutsche, SilverBow Resources Locations: U.S, Bank of America downgrades, NWL, Republic, Mohawk

Shanker also raised his price target to $80 from $75, suggesting nearly 34% downside from Friday's close. — Spencer Kimball 8:16 a.m.: Loop Capital upgrades Corteva, touts growth acceleration in 2025 Corteva's stronger-than-expected 2024 full-year guidance will jumpstart a period of strong growth, according to Loop Capital. The firm upgraded the agricultural chemicals company to buy from hold and increased its price target to $65 from $57. Analyst Jay Sole upgraded Urban to neutral from sell and upped his 12-month price target by $20 to $41. Kaufman's $183 price target indicates roughly 6.3% downside for shares, which have fallen more than 18% over the past year.

Persons: headwinds, Morgan Stanley downgrades XPO, Morgan Stanley, Ravi, Shanker, — Michelle Fox, Julien Dumoulin, Smith, Duke's, — Spencer Kimball, Chris Kapsch, Kapsch, Brian Evans, Cassie Chan, they'll, Chan, —, Jay Sole, URBN, Sole, Urban's, — Pia Singh, Filippo Falorni, Falorni, Hershey, Stanley, Pamela Kaufman, Kaufman's, Hershey's, Kaufman, Graham Doyle, Doyle, Piper Sandler, David Amsellem, Amsellem, Amsellam, Christopher Horvers, Jan, Horvers, Fred Imbert, Dan Levy, Levy Organizations: CNBC, Barclays, Automotive, JPMorgan, Corp, Bank of America, Bank of America downgrades Duke Energy, Duke Energy, Duke, Wall, America, UBS, Urban Outfitters, Free People, Urban, Citi, PepsiCo, Citi Research, Pepsi, Hershey, GE Healthcare Technologies, UBS GE Healthcare Technologies, Pharmaceutical, Teva Pharmaceutical, Federal, Barclays downgrades Rivian, Rivian Automotive, North American EV Locations: Bank of America downgrades, GEHC, David Amsellem U.S

☆ Here are Friday's biggest analyst calls: Apple, Alphabet, Tesla, Costco, Dick's, United, Pinterest, Vivid Seats & more
▼ + stars: | 2024-02-09 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Daiwa reiterates Apple as outperform Daiwa said it needs to see more growth from Apple, but that it's sticking with its outperform rating. " "We reiterate our Outperform rating on Dick's Sporting Goods and lift our 12- to 18- month price target to $190 (from $145)." Bank of America reiterates Pinterest as buy Bank of America said it's standing by Pinterest shares after earnings on Thursday. Initiating Coverage On Vivid Seats With A BUY Rating And $10 Price Target. Bank of America initiates Ocular Therapeutix as buy Bank of America said it's bullish on the opthalmic biotech company.

Persons: Morgan Stanley, it's, Wedbush, Tesla, Daiwa, Oppenheimer, Argus, Pinterest, Goldman Sachs, Goldman, Wells, Craig, Hallum, Cleveland, it's bullish Organizations: Citi, Liberty Global, Apple, Dick's Sporting Goods, Bank of America, HSBC, Bunge, Argus, Health, PayPal, Costco, Alphatec Holdings, United Airlines, Target ., JPMorgan, " Bank of America Locations: FCF, Cleveland

It is the first advertising company to reach a major settlement over the toll of opioids in the U.S. It faced a lawsuit in at least Massachusetts but settled with most states before they made court claims against it. James' office said the materials played up the abuse-deterrent properties of OxyContin and promoted increasing patients' doses. As part of the settlement, Publicis agreed to release internal documents detailing its work for Purdue and other companies that made opioids. The first began after OxyContin hit the market in 1996 and was linked mostly to prescription opioids, many of them generics.

Persons: Letitia James, Publicis, James, Bob Ferguson, Rosetta, ” Publicis, Sackler, OxyContin Organizations: Publicis, Publicis Groupe, New York, Purdue Pharma, Washington, Purdue, State Pharmacy, U.S, Supreme Locations: Paris, U.S, Massachusetts, Connecticut

☆ Novartis misses Q4 net income expectations, extends forecast
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, it said in a statement, missing analysts' estimate of about $3.3 billion, as per LSEG data. Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings. CEO Vas Narasimhan previously led a push to cut jobs and focus on fewer therapeutic areas and geographic markets, before spinning off and listing generic drugs business Sandoz late last year.

Persons: Sandoz, Vas Narasimhan Organizations: Novartis

☆ Here are Monday's biggest analyst calls: Nvidia, Netflix, Apple, Micron, Hershey, Dollar Tree, Qualcomm & more
▼ + stars: | 2024-01-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

JPMorgan upgrades Dollar Tree to overweight from neutral JPMorgan said in its upgrade of the stock that it's a "self-help" story. Bernstein upgrades Hershey to outperform from market perform Bernstein said in its upgrade of the chocolate maker that market share trends are improving. " Goldman Sachs reiterates Nvidia & Micron as buys Goldman said it's standing by shares of Nvidia and Micron. Bank of America upgrades ZoomInfo to buy from neutral Bank of America said the software company is a "self-help" story. Bernstein reiterates Qualcomm as outperform Bernstein said it's bullish heading into Qualcomm earnings later this week.

Persons: Wells, Jefferies, it's, Evercore, Bernstein, Hershey, Goldman Sachs, Goldman, Raymond James, Sherwin, Williams, Morgan Stanley, William Blair, Morgan Stanley downgrades Brown, Forman Organizations: UBS, Amazon, Amazon Web Services, Citi, Air, Deutsche Bank, TFI, Deutsche, JPMorgan, Warner Brothers Discovery, Microsoft, Meta, YouTube, Nvidia, Micron, MU, Netflix, Barclays, Apple, Colgate, Palmolive, " Bank of America, of America, Beam Therapeutics, Bank of America, Builders, Devices, AMD, Qualcomm Locations: Norfolk Southern, Atlanta

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Tyson Foods drops CVS for upstart pharmacy benefit manager, as industry upheaval over cost concerns spreads
▼ + stars: | 2024-01-24 | by ( Bertha Coombs | ) www.cnbc.com time to read: +1 min

Tyson Foods will become one of the first Fortune 100 companies to stop using the nation's traditional large pharmacy benefits managers, as it looks to cut spending on high-cost drugs. After putting its benefits contract up for bid, Tyson dropped CVS Health 's Caremark and chose PBM startup Rightway to manage drug benefits for its 140,000 employees starting this year, the companies said Wednesday. Tyson made the decision as it saw pharmacy costs soar. "We were going anywhere between 12% to 14% increases for pharmacy — and on a $200 million spend that's quite a bit. And then I wanted to understand what Tyson was paying for that; it was very difficult to get to those numbers," she said.

Persons: Tyson, Renu Chhabra, Chhabra, couldn't Organizations: Fortune, CVS

☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.

Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States

☆ Questions and answers for weight loss medications semaglutide and tirzepatide
▼ + stars: | 2024-01-17 | by ( Katia Hetter | ) edition.cnn.com time to read: +10 min

CNN —As prescriptions for popular weight loss drugs have soared, the class of medications known as GLP-1 agonists is changing the way people think about how to lose weight. Initially developed to treat type 2 diabetes, medications like semaglutide and tirzepatide have also been shown to be effective in promoting weight loss. Also, some people would do well without medications and could have sufficient weight loss with changes in diet and exercise. Wen: The FDA-approved versions of semaglutide and tirzepatide for weight loss are called Wegovy and Zepbound. CNN: Are there certain medications that preclude you from taking the weight loss drugs at the same time?

Persons: Leana Wen, Wen, Michael Siluk, tirzepatide, It’s, Eli Lilly Organizations: CNN, US Food and Drug Administration, George Washington University, FDA, BMI, Getty Images CNN, The New England, of Medicine, Novo Nordisk, semaglutide Locations: The

☆ US drug shortages are forcing ‘impossible choices’ for Americans, experts tell Senate committee
▼ + stars: | 2023-12-05 | by ( Jen Christensen | ) edition.cnn.com time to read: +7 min

Anderson Cancer Center in Houston, Dr. Jason Westin regularly witnesses the power of lifesaving cancer drugs. But because generic cancer drugs are often in shortage in the United States, he says, he and his patients have been put in a terrible position. Makers of generic drugs don’t have to share information about the supply chain, so buyers currently choose based only on price. Hernandez told the Senate committee that of the top 50 generic drugs paid for by Medicare Part D, 16 were marked up 1,000% or higher. Until there is some kind of legislation that addresses drug shortages, Wosińska and the other experts agreed, they will continue.

Persons: Jason Westin, ” Westin, that’s, they’d, Sen, Marsha Blackburn, Mike Crapo, Generics, ” Crapo, “, ”, Crapo, Inmaculada Hernandez, ” Hernandez, Dr, Marta E, it’s, ” Wosińska, Ron Wyden, ” Wyden, Hernandez, Sanjay Gupta Organizations: CNN, Anderson Cancer Center, US, Finance, Vanderbilt, Tennessee Republican, Food and Drug Administration, Westin, Skaggs School of Pharmacy, Pharmaceutical Sciences, University of California, Centers, Medicare, Medicaid Services, Brookings Institution, CNN Health Locations: M.D, Houston, United States, Nashville, Idaho, China, India, San Diego, Oregon, generics

☆ A comeback bet on a cheap drug stock that's missed the market rally and is at a 52-week low
▼ + stars: | 2023-11-29 | by ( Tony Zhang | ) www.cnbc.com time to read: +2 min

In a market that is trending higher, most stocks are trading at levels where the risk/reward is unfavorable to enter new long positions. During times like these, a contrarian view is required to find bullish opportunities where the risk/reward balance is still favorable. One such stock that is unloved by most analysts and trading at a new 52-week low is Bristol-Myers Squibb (BMY) , but that is why I think it's worth investigating. After declining nearly 40% over the past 12 months, BMY is starting to approach levels that should interest a long-term investor. Additionally, multiple drugs in their pipeline that have been approved this past year are starting to see strong quarter-over-quarter sales growth.

Persons: BMY Organizations: Myers Squibb, FDA Locations: Bristol

CAPE TOWN, South Africa (AP) — South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. The pills are especially important for South Africa, where TB killed more than 50,000 people in 2021, making it the country’s leading cause of death. In July, J&J’s patent on the drug expired in South Africa, but the company had it extended until 2027, enraging activists who accused it of profiteering. Back then, President Nelson Mandela’s government in South Africa eventually suspended patents to allow wider access to AIDS drugs. Bedaquiline was not rolled out as a standard treatment in South Africa until 2018.

Persons: they’ve, ”, Brook Baker, Johnson, Christophe Perrin, Peter Maybarduk, Petro Terblanche, Afrigen, Nelson Mandela’s, “ Mandela, Terblanche, Lynette Keneilwe Mabote, Andy Gray, Gray, Zolelwa, Bedaquiline, “, Sifumba, ___ Cheng Organizations: Health Organization, Northeastern University, One, Johnson, J, Viiv Healthcare, WHO, Public Citizen, Pfizer, Moderna, Terblanche, Big Pharma, South, University of KwaZulu, World Health Organization, AP Locations: CAPE, South Africa, Colombia, Belarus, Ukraine, Colombian, Washington, Africa, Natal, South African, London

A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Incretins are peptide-based drugs such as Mounjaro that mimic gut hormones to suppress appetite and stimulate insulin secretion. Lilly said it had announced investments of more than $11 billion in global manufacturing in the past three years. Major production sites that Lilly runs outside of its U.S. home market are in Ireland, France, Spain, Italy and China. The new Alzey site will employ up to 1,000 highly skilled workers such as engineers, technicians and scientists, said Lilly.

Persons: Eli Lilly, Mike Segar, Lilly, Karl Lauterbach, Lauterbach, generics, Patrick Wingrove, Matthias Williams, Jason Neely, David Evans Organizations: Company, REUTERS, Rights, Reuters, U.S ., Novo Nordisk, European Union, pharma, The U.S ., Thomson Locations: Branchburg , New Jersey, Germany, Alzey, U.S, United States, Danish, Berlin, Fegersheim, France, European, Indiana , North Carolina, Limerick, Ireland, Spain, Italy, China, The U.S

Many of the patents at issue in the Food and Drug Administration's Orange Book listing of approved products were for devices such as asthma inhalers and epinephrine autoinjectors, the FTC said. "Wrongfully listed Orange Book patents by pharma companies can raise drug prices for Americans, harm fair competition, and delay better drugs," FTC Chair Lina Khan said on X, formerly known as Twitter. The Orange Book identifies drugs and products that the FDA has deemed safe and effective. The FTC says companies sometimes improperly list patents in the Orange Book that can delay market entry of lower priced generics. AbbVie was informed the FTC would dispute four patents in the Orange Book having to do with Restasis Multidose, eye drops used for chronic dry eye.

Persons: Andrew Kelly, Lina Khan, Boehringer Ingelheim, Mylan, AbbVie, Restasis, Diane Bartz, Patrick Wingrove, Bill Berkrot Organizations: Food and Drug Administration, FDA, REUTERS, AstraZeneca, GSK, U.S . Federal Trade Commission, Food, FTC, pharma, Thomson Locations: White Oak , Maryland, U.S, WASHINGTON, Israel, Viatris

☆ EU proposal may accelerate pharma innovation decline, industry group says
▼ + stars: | 2023-11-06 | by ( Julia Payne | ) www.reuters.com time to read: +3 min

"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said. Medication was the single biggest contributor to the EU’s trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021. The EFPIA said small biotech companies have already moved to the United States and China. The Commission said its proposal would reduce new medicine approval times to 180 days from 400 days. Germany, Belgium and France would be the hardest hit by the proposed rules, the EFPIA said citing research by Dolon that it commissioned.

Persons: EFPIA, Lars Fruergaard Jorgensen, Jorgensen, Ozempic, " Jorgensen, Julia Payne, Lisa Shumaker Organizations: European Commission, European Federation of Pharmaceutical Industries, EU, Commission, Novo Nordisk, Thomson Locations: BRUSSELS, United States, China, Danish, Boston, U.S, Europe, EU, Germany, Belgium, France

☆ Novartis' Sandoz valued at $11.2 bln in market debut
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +1 min

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 4 (Reuters) - Sandoz (SDZ.S) made its market debut with a lower-than-expected valuation of 10.3 billion Swiss francs ($11.2 billion) on Wednesday, after the generic and biosimilar drugmaker was spun off from Swiss pharmaceutical company Novartis (NOVN.S). Deutsche Bank had said Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, would likely be valued at $11-$13 billion, while brokerage Berenberg had forecast $17-$26 billion. The shares, which opened at 24 Swiss francs, became members of the Swiss Performance Index and the Swiss Leader Index, among other stock market gauges, and American depositary receipts also started trading on Wednesday. Novartis shareholders received one Sandoz share for every five Novartis shares they held as part of the transaction.

Persons: Brian Snyder, drugmaker, Sandoz, Berenberg, Vas Narasimhan, Ludwig Burger, Tristan Veyet, Clarence Fernandez, Mark Potter Organizations: Novartis, Research, REUTERS, Sandoz, Analysts, Deutsche Bank, Swiss, Thomson Locations: Cambridge , Massachusetts, U.S, Swiss, generics

☆ Stocks making the biggest moves premarket: Cal-Maine Foods, Intel, Apple & more
▼ + stars: | 2023-10-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Intel — Shares popped 2.5% after the chipmaker announced it would be operating its programmable chip unit as a standalone business complete. Intel plans to conduct an initial public offering for the unit within the next two to three years. The firm is bullish on the stock thanks to progress on legacy projects and said Fluor is on the brink of a company turning point. Sunrun , Sunnova Energy International — Shares of Sunrun and Sunnova dropped 3% and 2.8%, respectively, after Truist Securities downgraded the solar panel installers to hold from buy on Wednesday. Cal-Maine Foods — The stock plunged 11.6% after the company came out with disappointing sales figures due to lower prices.

Persons: Fluor, Sunnova, Moderna, StreetAccount, — CNBC's Brian Evans, Lisa Han Organizations: Intel, UBS, Apple, Sunnova Energy, Truist Securities, Moderna, pharma, Bank of America, Novartis —, Swiss drugmaker, Sandoz, SIX Swiss Exchange, Maine Foods, Revenue Locations: United States, Israel, Swiss, Cal

Search resuls for: "Generics"

25 mentions found